Oncternal Therapeutics, Inc. announced that following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for zilovertamab, the company's investigational anti-ROR1 monoclonal antibody, the company and the FDA agreed on key elements of the company's potentially pivotal Phase 3 clinical trial of zilovertamab for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL). The FDA has also reviewed and agreed upon the key design features and operational details of the company's Phase 3 clinical trial protocol and Statistical Analysis Plan, which is being finalized based on the FDA's input.